Guggenheim Downgrades Aerovate Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Vamil Divan has downgraded Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Neutral.
June 18, 2024 | 4:51 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Guggenheim analyst Vamil Divan has downgraded Aerovate Therapeutics from Buy to Neutral, which may lead to a short-term decline in the stock price.
The downgrade from Buy to Neutral by a reputable analyst like Vamil Divan at Guggenheim is likely to negatively impact investor sentiment and lead to a short-term decline in AVTE's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100